Search clinical trials for: NSCLC Recurrent

Total 15248 results

Bristol-Myers Squibb

Active, not recruiting

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

Australia, Russian Federation, United States, Argentina, Austria, Belgium, Brazil, Chile, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Romania, Spain, Switzerland, United Kingdom
NCIC Clinical Trials Group
GlaxoSmithKline

Completed

MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy

Lung Cancer

Canada
NCIC Clinical Trials Group

Completed

AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)

Colorectal Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

Canada
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Stand Up To Cancer; Iovance Biotherapeutics, Inc.; Prometheus...

Completed

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Adenocarcinomas | Squamous Cell Carcinoma | Advanced NSCLC | Metastatic Non-small Cell Lung Cancer | Adenosquamous Carcinoma

United States
Rain Oncology Inc

Terminated

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (RAIN)

NSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB Fusion

United States, Canada, Hong Kong
AbbVie
Pfizer

Active, not recruiting

An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

Cancer | Non-small Cell Lung Cancer (NSCLC)

United States, Israel, Japan, Korea, Republic of, Spain, Taiwan
H. Lee Moffitt Cancer Center and Research Institute

Completed

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

Renal Cell Carcinoma | Non-Small Cell Lung Cancer | NSCLC | Solid Tumor | Metastatic Cancer | Squamous Cell Carcinoma of the Head and Neck | Urothelial Carcinoma | Squamous Cell Carcinoma | Recurrent Cancer

United States
Nasser Hanna
Genentech, Inc.

Terminated

Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

NSCLC Stage IV | NSCLC, Recurrent

United States
ETOP IBCSG Partners Foundation
Hoffmann-La Roche

Terminated

ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer (ALERT-lung)

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Recurrent

Ireland, Spain, Belgium, Italy, Netherlands, Switzerland
University of Utah

Completed

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

Cancer | Non Small Cell Lung Cancer

United States
Eli Lilly and Company
Bristol-Myers Squibb

Completed

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

Solid Tumor | Hepatocellular Carcinoma Recurrent | Non-Small Cell Lung Cancer Recurrent

Spain, United States
Innovent Biologics (Suzhou) Co. Ltd.
WuXi CDS Clinical Research (Shanghai) Co.Ltd.

Completed

Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC

NSCLC

China
Royal Marsden NHS Foundation Trust
Boehringer Ingelheim; Celgene

Withdrawn

Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma (N3)

Adenocarcinoma of Lung | NSCLC, Recurrent
Famewave Ltd.

Terminated

Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)

Melanoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Bladder Cancer | Non-small Cell Lung Carcinoma (NSCLC)

United States, Israel
The Netherlands Cancer Institute
Merck Sharp & Dohme LLC

Completed

Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC (PEMBRO-RT)

Non-Small Cell Lung Cancer

Netherlands
Shanghai Cancer Hospital, China

Unknown

Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study

Lung Neoplasms

China
Clovis Oncology, Inc.

Terminated

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Korea, Republic of, Germany, Taiwan, Australia, Hong Kong, Netherlands, Spain, France, United Kingdom, Canada, Switzerland
Clovis Oncology, Inc.

Terminated

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Locally Advanced or Metastatic Non Small Cell Lung Cancer

United States, Australia, France, Poland
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Withdrawn

Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Etirinotecan Pegol (NKTR-102) in NSCLC

Metastatic Non Small Cell Lung Cancer | Recurrent Non Small Cell Lung Cancer

United States
Helix BioPharma Corporation
Theradex

Completed

A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC

Non-Small Cell Lung Cancer

United States
Eli Lilly and Company

Completed

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States, Germany, Poland, Belgium, Canada, United Kingdom
Maastricht Radiation Oncology
University of Pennsylvania; University of Wisconsin, Madison

Completed

Photon Versus Particle Therapy for Recurrent Lung Cancer; a Planning Study Based on a Reference Dataset of Patients.

NSCLC

Netherlands
Clovis Oncology, Inc.

Terminated

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Non-small Cell Lung Cancer

Korea, Republic of, United States, France, Germany, Netherlands, Australia, Spain, Taiwan, United Kingdom, Italy
Celgene

Completed

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Breast Neoplasms | Pancreatic Neoplasms

United States
Swiss Group for Clinical Cancer Research

Completed

Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC

Lung Cancer

Switzerland
Clovis Oncology, Inc.

Terminated

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy (EGFR)

Non-Small Cell Lung Cancer

Korea, Republic of, United States, Spain, Hong Kong, Taiwan, Germany, Italy
Halozyme Therapeutics

Terminated

A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC (PRIMAL)

Non-small Cell Lung Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC

Recurrent Non Small Cell Lung Cancer

United States, Singapore
Seoul National University Hospital
MACROGEN

Unknown

Cancer Panel From Blood of Lung Cancer Patients (CAPABLE)

Non Small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer Recurrent

Korea, Republic of
Guangzhou Institute of Respiratory Disease
Guangdong Xiangxue Precision Medical Technology Co., Ltd.; Xiangxue Life Science... and other collaborators

Unknown

NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC

Lung Cancer, Nonsmall Cell, Recurrent

China
American College of Radiology Imaging Network
National Cancer Institute (NCI)

Terminated

FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy (ACRIN6678)

Lung Cancer

United States
National Cancer Institute (NCI)

Completed

AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

Canada
SCRI Development Innovations, LLC
Achieve Life Sciences

Completed

Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer (Spruce)

Non Squamous Non Small Cell Lung Cancer

United States
Sun Yat-sen University

Unknown

Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC (SEQUENCE)

Non Small Cell Lung Cancer

China
M.D. Anderson Cancer Center
AstraZeneca; MedImmune LLC

Withdrawn

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma | Advanced Lung Cancer | Recurrent Nonsmall Cell Lung Cancer
Incyte Corporation

Terminated

Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

NSCLC (Non-small Cell Lung Carcinoma)

United States
VA Office of Research and Development
National Cancer Institute (NCI); Jonsson Comprehensive Cancer Center

Terminated

A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer (VTNSCLC)

Non-Small Cell Lung Cancer (NSCLC)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Terminated

Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)

Non-small-cell Lung Cancer

United States
Masonic Cancer Center, University of Minnesota

Terminated

Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC

Lung Cancer

United States
New Mexico Cancer Care Alliance

Terminated

IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors

Recurrent Non-small Cell Lung Cancer

United States
Boehringer Ingelheim

Terminated

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

Carcinoma, Non-Small-Cell Lung | ErbB Receptors

United States
UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb

Terminated

Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC

Lung Cancer

United States
Ohio State University Comprehensive Cancer Center

Withdrawn

Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation

Fatigue | Cachexia | Radiation Toxicity | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Pulmonary Complications | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer
Asbestos Diseases Research Foundation
EnGeneIC Limited

Completed

MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC

Non-Small Cell Lung Cancer | Malignant Pleural Mesothelioma

Australia
H. Lee Moffitt Cancer Center and Research Institute
Sanofi

Terminated

Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem

Lung Cancer

United States
National Cancer Institute (NCI)

Completed

A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC

Stage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-Small-Cell Lung Carcinoma

United States
M.D. Anderson Cancer Center
Janssen Scientific Affairs, LLC

Withdrawn

Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer, Nonsmall Cell, Stage I
Washington University School of Medicine

Terminated

Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States

Search clinical trials for: NSCLC Recurrent

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations